Value-based care is at the centre of industry discussions at the moment, not only advancing quality and equity in healthcare, but also accelerating innovation in care delivery.
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s po
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
The UK government plans to link the NHS App to data generated by smart devices, including step counts and heart rate, for example, according to Health Secretary Victoria A
Over the years, pharmacovigilance (PV) processes have relied on PV professionals manually sifting through large volumes of data to identify, assess, and report Adverse Event (AE) informatio
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh